DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellscancerbevacizumabperitonealhla
  Phrases that lowered it: participantdruginvestigatorclinical trialother clinical
• Sponsor's past termination rate: 23.6% (raises risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 59.5% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 5.5% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: none (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Keywords listed: 0 (raises risk) · Design
• Sponsor's past trials: 89 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, urogenital: Yes (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03206047 · started 2017 · scored riskier than 78% of active trials completed
• CT Antigen TCR-redirected T Cells for Ovarian Cancer. NCT01567891 · started 2013 · scored riskier than 91% of active trials completed
• Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 NCT02775292 · started 2017 · scored riskier than 92% of active trials completed
• Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) NCT02862457 · started 2016 · scored riskier than 36% of active trials completed
• A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers NCT02923934 · started 2017 · scored riskier than 87% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.